MicroRNAs and prostate cancer: From preclinical research to translational oncology

Cancer Journal (United States)

Volumn 18, Issue 3, 2012, Pages 253-261

  Maugeri Saccà, Marcello ^a   Coppola, Valeria ^b   Bonci, Désirée ^b   De Maria, Ruggero ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

biomarkers; microRNAs; prostate cancer

Indexed keywords

ANDROGEN; MICRORNA; MICRORNA 125B; MICRORNA 143; MICRORNA 145; MICRORNA 16; MICRORNA 182; MICRORNA 205; MICRORNA 20A; MICRORNA 221; MICRORNA 222; MICRORNA 29;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE REGULATION; DOWN REGULATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862186491     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318258b5b6     Document Type: Review

References (114)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
2. Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer. 2011;117:1123-1135.
3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 2010;376:1147-1154.
4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
5. de Bono JS, Logothetis CJ,Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
6. Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 2009;27:5848-5856.
7. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
8. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415-419.
9. Hutvagner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293:834-838.
10. Peters L, Meister G. Argonaute proteins: Mediators of RNA silencing. Mol Cell. 2007;26:611-623.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20.
12. Bianchi F, Nicassio F, Marzi M, et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med. 2011;3:495-503.
13. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108: 3713-3718.
14. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361:1437-1447.
15. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17:F1-17.
16. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261.
17. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162-6170.
18. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130-6135.
19. OzenM, CreightonCJ,OzdemirM, et al.Widespread deregulation ofmicro- RNAexpression in human prostate cancer.Oncogene. 2008;27:1788-1793.
20. Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009;16:206-216.
21. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166-1176.
22. Szczyrba J, Loprich E, Wach S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res. 2010;8: 529-538.
23. Martens-Uzunova ES, Jalava SE, Dits NF, et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer [published online ahead of print]. Oncogene. 2012;31:978-991.
24. Watahiki A,Wang Y, Morris J, et al. MicroRNAs associated with metastatic prostate cancer. PLoS One. 2011;6:e24950.
25. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104:19983-19988.
26. Shi XB, Xue L, Ma AH, et al. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011;71:538-549.
27. Sun D, Lee YS, Malhotra A, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 2011;71:1313-1324.
28. Peng X, GuoW, Liu T, et al. Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011;6:e20341.
29. Clape C, Fritz V, Henriquet C, et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One. 2009;4:e7542.
30. Zaman MS, Chen Y, Deng G, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010;103:256-264.
31. Fuse M, Nohata N, Kojima S, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38:1093-1101.
32. Suh SO, Chen Y, Zaman MS, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011;32:772-778.
33. Chiyomaru T, Tatarano S, Kawakami K, et al. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR- 145 in prostate cancer. Prostate. 2011 Feb 25. doi: 10.1002/pros.21372. [Epub ahead of print].
34. Bonci D, Coppola V, Musumeci M, et al. The miR-15aYmiR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271-1277.
35. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation ofmultiple cell-cycle genes. Mol Ther. 2010;18:181-187.
36. Mihelich BL, Khramtsova EA, Arva N, et al. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem. 2011;286:44503-44511.
37. Gandellini P, FoliniM, Longoni N, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287-2295.
38. Bhatnagar N, Li X, Padi SK, et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis. 2010;1:e105.
39. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282:2135-2143.
40. Pesta M, Klecka J, Kulda V, et al. Importance of miR-20a expression in prostate cancer tissue. Anticancer Res. 2010;30:3579-3583.
41. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282:23716-23724.
42. Mercatelli N, Coppola V, Bonci D, et al. The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008;3:e4029.
43. Sun T, Wang Q, Balk S, et al. The role of microRNA-221 and micro- RNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356-3363.
44. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR- 23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762-765.
45. Poliseno L, Salmena L, Riccardi L, et al. Identification of the miR-1- 06bÉ25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010;3:ra29.
46. Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating micro- RNA levels associated with prostate cancer. Br J Cancer. 2012;106: 768-774.
47. Porkka KP, Ogg EL, Saramaki OR, et al. The miR-15aYmiR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer. 2011;50:499-509.
48. Noonan EJ, Place RF, Basak S, et al. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget. 2010;1:349-358.
49. Dong Q, Meng P,Wang T, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 2010;5:e10147.
50. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635-647.
51. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007;67:9762-9770.
52. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007;315: 1576-1579.
53. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447:1130-1134.
54. Bommer GT, Gerin I, Feng Y, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298-1307.
55. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26: 731-743.
56. Chang TC,Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745-752.
57. Tazawa H, Tsuchiya N, Izumiya M, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104:15472-15477.
58. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114-119.
59. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A. 2008;105:13421-13426.
60. Hagman Z, Larne O, Edsjo A, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer. 2010;127:2768-2776.
61. Lee KH, Chen YL, Yeh SD, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1- mediated suppression of Akt phosphorylation. Oncogene. 2009;28: 3360-3370.
62. Chen X, Gong J, Zeng H, et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res. 2010;70:2728-2738.
63. Sowter HM, Ratcliffe PJ, Watson P, et al. HIF-1Ydependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669-6673.
64. Lin SL, Chiang A, Chang D, et al. Loss of mir-146a function in hormone- refractory prostate cancer. RNA. 2008;14:417-424.
65. Lin SL, Chang D, Ying SY. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis. 2007;28:310-320.
66. Xu B, Wang N,Wang X, et al. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERKYdependent manner in castration-resistant prostate cancer [published online ahead of print]. Prostate. 2011 Dec 7. doi: 10.1002/pros.22466. [Epub ahead of print].
67. Fujita Y, Kojima K, Ohhashi R, et al. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem. 2010;285:19076-19084.
68. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8:357-368.
69. Christofori G. New signals from the invasive front. Nature. 2006;441: 444-450.
70. Chaffer CL,Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
71. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350:1655-1664.
72. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23: 4925-4935.
73. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377: 813-822.
74. Itoh K, Yoshioka K, Akedo H, et al. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999;5: 221-225.
75. Bourguignon LY, Singleton PA, Zhu H, et al. Hyaluronan-mediatedCD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003;278:29420-29434.
76. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008;10:788-801.
77. Wang J, Loberg R, Taichman RS. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006;25: 573-587.
78. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820-827.
79. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121: 335-348.
80. Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17: 5287-5298.
81. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66:6063-6071.
82. Lawson DA,Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest. 2007;117:2044-2050.
83. Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461:495-500.
84. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res. 2011;17:4942-4947.
85. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988.
86. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211-215.
87. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695-1699.
88. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27:7274-7284.
89. Cao P, Deng Z,Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 2010;9:108.
90. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: A diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2011 Nov 19. [Epub ahead of print].
91. Musumeci M, Coppola V, Addario A, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011;30:4231-4242.
92. Karaa ZS, Iacovoni JS, Bastide A, et al. The VEGF IRESes are differentially susceptible to translation inhibition by miR-16. RNA. 2009;15: 249-254.
93. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011; 57:1366-1375.
94. Boyerinas B, Park SM, Hau A, et al. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17:F19YF36.
95. Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012;287:1527-1537.
96. Ostling P, Leivonen SK, Aakula A, et al. Systematic analysis of micro- RNAs targeting the androgen receptor in prostate cancer cells. Cancer Res. 2011;71:1956-1967.
97. Narayanan R, Jiang J, Gusev Y, et al. MicroRNAs are mediators of androgen action in prostate and muscle. PLoS One. 2010;5:e13637.
98. Takayama K, Tsutsumi S, Katayama S, et al. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene. 2011;30:619-630.
99. Ribas J, Ni X, Haffner M, et al. miR-21: An androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69:7165-7169.
100. Jalava SE, Urbanucci A, Latonen L, et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. 2012 Jan 23. doi: 10.1038/onc.2011.624. [Epub ahead of print].
101. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalinfixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36.
102. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13:1668-1674.
103. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
104. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13:1248-1260.
105. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21.
106. Zhou L, Zhao YP, Liu WJ, et al. Circulating microRNAs in cancer: Diagnostic and prognostic significance. Expert Rev Anticancer Ther. 2012;12:283-288.
107. Mitchell PS, Parkin RK, Kroh EM, et al Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
108. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating micro- RNAs as potential biomarkers for prostate cancer [published online ahead of print]. Prostate. 2012.
109. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011;71:550-560.
110. Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012 Feb 1. doi: 10.1002/pros.22499. [Epub ahead of print].
111. Long Q, Johnson BA, Osunkoya AO, et al. Protein-coding and micro- RNA biomarkers of recurrence of prostate cancer following radical prostatectomy. Am J Pathol. 2011;179:46-54.
112. Bao BY, Pao JB, Huang CN, et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res. 2011;17:928-936.
113. Zhang HL, Yang LF, Zhu Y, et al. Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71:326-331.
114. Gonzales JC, Fink LM, Goodman OB, Jr. et al. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9:39-45.